Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Current Opinion in HIV and AIDS|April 18, 2009
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitorsMadhavi N L Nalam, Celia A SchifferJournal of Virology|June 29, 2007
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 proteaseMadhavi N L Nalam, Anik Peeters, Tim H M Jonckers, et al.Journal of the American Chemical Society|February 3, 2012
Hydrophobic core flexibility modulates enzyme activity in HIV-1 proteaseSeema Mittal, Yufeng Cai, Madhavi N L Nalam, et al.Proceedings of the National Academy of Sciences of the United States of America|May 20, 2003
Programming peptidomimetic syntheses by translating genetic codes designed de novoAnthony C Forster, Zhongping Tan, Madhavi N L Nalam, et al.ACS Chemical Biology|August 20, 2013
Testing the substrate-envelope hypothesis with designed pairs of compoundsYang Shen, Michael D Altman, Akbar Ali, et al.Journal of Medicinal Chemistry|October 21, 2010
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinonesAkbar Ali, G S Kiran Kumar Reddy, Madhavi N L Nalam, et al.Journal of Medicinal Chemistry|December 8, 2006
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligandsAkbar Ali, G S Kiran Kumar Reddy, Hong Cao, et al.Journal of Medicinal Chemistry|June 20, 2012
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistanceMaloy Kumar Parai, David J Huggins, Hong Cao, et al.Journal of Virology|February 1, 2013
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50Seema Mittal, Rajinthna M Bandaranayake, Nancy M King, et al.Antimicrobial Agents and Chemotherapy|September 8, 2011
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitorsInge Dierynck, Herwig Van Marck, Marcia Van Ginderen, et al.Pageof 2